EBV/LMP特异性T细胞在同种异体骨髓移植后维持T细胞和B细胞EBV淋巴瘤的缓解
研究评估供者来源的EBV潜伏膜蛋白特异性T细胞(LMP-Ts)在26例因EBV相关自然杀伤/T细胞或B细胞淋巴瘤接受同种异体造血干细胞移植的患者中的安全性和有效性;7例用于活动性疾病治疗,19例用于高危疾病辅助治疗;未见立即发生的输注相关毒性,仅1例剂量限制性毒性可能与T细胞输注相关;2年总生存率为68%,移植后完全缓解期接受T细胞治疗者2年总生存率为78%。
要点
- 供者来源LMP-Ts未见立即输注相关毒性,仅1例剂量限制性毒性可能与输注相关。
- 移植后完全缓解期接受T细胞治疗者2年总生存率为78%。
- 作者认为供者来源LMP-Ts是预防移植后复发安全有效的辅助治疗。
核心结论
- 作者认为供者来源LMP-Ts是预防B细胞或T细胞来源EBV相关淋巴瘤或淋巴增殖性疾病患者移植后复发的安全有效治疗,并支持将LMP-Ts作为辅助治疗以改善移植后结局。
研究设计与样本
- 研究评估供者来源LMP-Ts在26例因EBV相关自然杀伤/T细胞或B细胞淋巴瘤接受同种异体造血干细胞移植的患者中的安全性和有效性;7例用于活动性疾病治疗,19例用于高危疾病辅助治疗。
- 这些试验在www.clinicaltrials.gov注册,注册号为#NCT00062868和#NCT01956084。
主要发现
- 未见立即发生的输注相关毒性,仅见1例剂量限制性毒性可能与T细胞输注相关。
- 2年总生存率为68%;移植后完全缓解期接受T细胞治疗者2年总生存率为78%。
- B细胞疾病患者(n=10)2年总生存率为80%;T细胞疾病患者2年总生存率为60%,作者认为这提示较已发表移植后2年总生存率30%至50%有所改善。
临床怎么用
- 作者认为供者来源LMP-Ts是预防移植后复发的安全有效治疗,并支持将LMP-Ts作为辅助治疗以改善移植后结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous T cells targeting Epstein-Barr virus (EBV) latent membrane proteins (LMPs) have shown safety and efficacy in the treatment of patients with type 2 latency EBV-associated lymphomas for whom standard therapies have failed, including high-dose chemotherapy followed by autologous stem-cell rescue. However, the safety and efficacy of allogeneic donor-derived LMP-specific T cells (LMP-Ts) have not been established for patients who have undergone allogeneic hematopoietic stem-cell transplantation (HSCT). Therefore, we evaluated the safety and efficacy of donor-derived LMP-Ts in 26 patients who had undergone allogeneic HSCT for EBV-associated natural killer/T-cell or B-cell lymphomas. Seven patients received LMP-Ts as therapy for active disease, and 19 were treated with adjuvant therapy for high-risk disease. There were no immediate infusion-related toxicities, and only 1 dose-limiting toxicity potentially related to T-cell infusion was seen. The 2-year overall survival (OS) was 68%. Additionally, patients who received T-cell therapy while in complete remission after allogeneic HSCT had a 78% OS at 2 years. Patients treated for B-cell disease (n = 10) had a 2-year OS of 80%. Patients with T-cell disease had a 2-year OS of 60%, which suggests an improvement compared with published posttransplantation 2-year OS rates of 30% to 50%. Hence, this study shows that donor-derived LMP-Ts are a safe and effective therapy to prevent relapse after transplantation in patients with B cell- or T cell-derived EBV-associated lymphoma or lymphoproliferative disorder and supports the infusion of LMP-Ts as adjuvant therapy to improve outcomes in the posttransplantation setting. These trials were registered at www.clinicaltrials.gov as #NCT00062868 and #NCT01956084.
引用
- McLaughlin LP, Rouce R, Gottschalk S, et al. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018. PMID: 30262660. doi:10.1182/blood-2018-07-863654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。